Entering text into the input field will update the search result below

Akouos soars 87% as Lilly nabs hearing loss gene therapy developer

Oct. 18, 2022 7:25 AM ETEli Lilly and Company (LLY) StockBy: Ravikash, SA News Editor2 Comments

Eli Lilly and Company Research Laboratories. Lilly makes Medicines and Pharmaceuticals.

jetcityimage/iStock Editorial via Getty Images

Eli Lilly (NYSE:LLY) is acquiring hearing loss gene therapy maker Akouos (NASDAQ:AKUS) for ~$487M plus contingent value right (CVR) worth up to $610M.

Under the agreement, Lilly will begin a tender offer to acquire all the outstanding shares

Recommended For You

Comments (2)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

bazooooka profile picture
The CVR might be worth a punt on
In future if the trial results look good, LLY share will further shoot up.

About LLY

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Eli Lilly and Company
Johnson & Johnson
Merck & Co., Inc.
Roche Holding AG
AstraZeneca PLC
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.